Syndax Pharmaceuticals, Inc.
SNDX
Updated: 23/09/2026, 18:08:03
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
No summaries found.
- Share price
- $17.29
- Market cap
- $1.53B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Michael A. Metzger
- Employees
- 298
- IPO date
- 02/03/2016
- Beta
- 0.371
- Last dividend
- $0.00
- Day range
- $17.10 – $18.47
- 52-week range
- $12.99 – $25.59
- 1-day performance
- -4.95%
- 1-year performance
- 33.06%
- Current drawdown (1Y)
- -32.45%
- CIK
- 0001395937
- CUSIP
- 87164F105
- ISIN
- US87164F1057
- Created
- 07/12/2025, 14:18:41
- Last update
- 23/09/2026, 18:08:03
Track Syndax Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move SNDX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
GlobeNewsWire • STOCK • 11/06/2026, 09:03:00
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha • STOCK • 10/06/2026, 15:12:10
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 18:28:32
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 04/06/2026, 18:01:00
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
GlobeNewsWire • STOCK • 04/06/2026, 09:00:00
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
GlobeNewsWire • STOCK • 02/06/2026, 18:01:00
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
GlobeNewsWire • STOCK • 21/05/2026, 19:01:00
Syndax Announces Participation in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 20/05/2026, 09:00:00
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 06/05/2026, 18:01:00
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 01/05/2026, 00:51:35
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research • STOCK • 30/04/2026, 20:30:17
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
GlobeNewsWire • STOCK • 24/04/2026, 09:00:00